Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors

被引:1017
作者
Fattovich, Giovanna [1 ]
Bortolotti, Flavia [2 ]
Donato, Francesco [3 ]
机构
[1] Univ Verona, Dept Surg & Gastroenterol Sci, I-37134 Verona, Italy
[2] Univ Padua, Med Clin 5, Padua, Italy
[3] Univ Brescia, Inst Hyg Epidemiol & Publ Hlth, Brescia, Italy
关键词
chronic hepatitis B; natural history; prognostic factors;
D O I
10.1016/j.jhep.2007.11.011
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The natural history of chronic hepatitis B virus (HBV) infection and disease is complex and highly variable. We review the natural history of chronic hepatitis B with emphasis on the rates of disease progression and factors influencing the course of the liver disease. Chronic hepatitis B is characterized by an early replicative phase (HBeAg positive chronic hepatitis) and a late low or non-replication phase with HBeAg seroconversion and liver disease remission (inactive carrier state). Most patients become inactive carriers after spontaneous HBeAg seroconversion with good prognosis, but progression to HBeAg negative chronic hepatitis due to HBV variants not expressing HBeAg occurs at a rate of 1-3 per 100 person years following HBeAg seroconversion. The incidence of cirrhosis appears to be about 2-fold higher in HBeAg negative compared to HBeAg positive chronic hepatitis. In the cirrhotic patient the 5-year cumulative risk of developing hepatocellular carcinoma is 17% in East Asia and 10% in the Western Europe and the United States and the 5-year liver related death rate is 15% in Europe and 14% in East Asia. There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B. (c) 2007 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:335 / 352
页数:18
相关论文
共 152 条
  • [1] Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance
    Ahn, SH
    Park, YN
    Park, JY
    Chang, HY
    Lee, JM
    Shin, JE
    Han, KH
    Park, C
    Moon, YM
    Chon, CY
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 (02) : 188 - 194
  • [2] [Anonymous], METAANALYSIS DECISIO
  • [3] Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal
    Bataller, R
    North, KE
    Brenner, DA
    [J]. HEPATOLOGY, 2003, 37 (03) : 493 - 503
  • [4] BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO
  • [5] 2-J
  • [6] Benvegnù L, 1998, CANCER-AM CANCER SOC, V83, P901, DOI 10.1002/(SICI)1097-0142(19980901)83:5<901::AID-CNCR15>3.0.CO
  • [7] 2-Z
  • [8] Natural history of compensated viral cirrhosis:: a prospective study on the incidence and hierarchy of major complications
    Benvegnù, L
    Gios, M
    Boccato, S
    Alberti, A
    [J]. GUT, 2004, 53 (05) : 744 - 749
  • [9] Impact of non-alcoholic fatty liver disease on chronic hepatitis B
    Bondini, Silvia
    Kallman, Jillian
    Wheeler, Angela
    Prakash, Shivaani
    Gramlich, Terry
    Jondle, Daniel M.
    Younossi, Zobair M.
    [J]. LIVER INTERNATIONAL, 2007, 27 (05) : 607 - 611
  • [10] Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period
    Bortolotti, F
    Jara, P
    Crivellaro, C
    Hierro, L
    Cadrobbi, P
    Frauca, E
    Camarena, C
    De La Vega, A
    Diaz, C
    De Moliner, L
    Noventa, F
    [J]. JOURNAL OF HEPATOLOGY, 1998, 29 (02) : 184 - 190